Biogen Stock News

Stifel has downgraded shares of Biogen (BIIB) to but from hold amidst several factors, notable concerns over the likelihood that Alzheimers treatment lecanemab wins approval.

Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri Holdings Limited (NYSE:

Biogen stock is near a multi-year low. The pipeline of potential new drugs is deep.

Charles Schwab (SCHW) will replace Biogen (BIIB) in the S&P 100 index

One last look at Alzheimer's drug Aduhelm and Medicare

In the latest trading session, Biogen Inc. (BIIB) closed at $209.45, marking a -0.84% move from the previous day.

NEW YORK, March 4, 2022: S&P Dow Jones Indices will make the following changes to the S&P 100, S&P MidCap 400 and S&P SmallCap 600: • S&P 500 constituent The Charles Schwab Corp. (NYSE: SCHW) will replace Biogen Inc. (NASD: BIIB) in the S&P 100 effective prior to the opening of trading on Monday, March 21 to coincide with the quarterly rebalance. Biogen will remain in the S&P 500.

The Sackler family members who own Purdue Pharma agreed to pay up to $6 billion to settle a bankruptcy plan and issued a statement regretting their role in the opioid…

TOKYO and CAMBRIDGE, Mass. , March 3, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Corporate headquarters: Cambridge, Massachusetts , CEO: Michel Vounatsos , ", Biogen", )) announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401). The lecanemab Clarity AD Phase 3 clinical study for mild cognitive impairment (MCI) due to Alzheimer''s disease (AD) and mild AD (collectively known as early AD) is ongoing. The PMDA''s process, known as "prior assessment consultation," is conducted at the development stage before the new drug application submission, which is based on available quality, non-clinical and clinical data. By identifying and resolving any potential issues prior to submission, the aim is to shorten application review time.

Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhelm approval. An analyst at RBC Capital Markets has now turned

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7 12 0 0 Last 30D 0 1

Biogen (BIIB) has laid off more than 100 workers -- the vast majority in its Alzheimers division -- as a result of the commercial failure of its Alzheimers treatment Aduhelm.

Biogen stock popped Thursday after an analyst suggested it could reap $8 billion in sales of its Alzheimer''s treatments.